VICL News and Press, Vical Incorporated

Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...

Anti-retroviral therapy (ART), or highly-active-antiretroviral therapy (HAART), is effective in halting the progression of HIV infection (a disease affecting nearly 40 million persons worldwide). However, HAART does not cure the disease as the HIV virus, despite the treatment, remains hidden in ...

Vical ( VICL -20% ) approves the proposal to merge with Brickell Biotech and the transaction is expected to close on August 31, 2019. More news on: Vical Incorporated, Merger & acquisition news, Read more ...

•  Merger Transaction Expected to Close August 31, 2019 SAN DIEGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Vical Incorporated (“Vical”) (Nasdaq:VICL) announced that its stockholders voted to approve the proposals required to complete the merger transaction with Bric...

NEW YORK , Aug. 8, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law rela...

NEW YORK, NY / ACCESSWIRE / July 31, 2019 / Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York City, is investigating: ...

Chiyoda ( CHYCF ) reassignment Chiyoda (6366 JP), a global (based in Japan) engineering company, which specializes in oil and gas midstream for LNG and gas processing, has announced a reassignment to another sector of Tokyo Stock exchange. This might present an interesting short opportun...

Vical ( VICL ) is a failed biopharmaceutical company which discontinued operations in February 2019 to seek strategic alternatives. On June 3rd, Vical announced the proposed merger with Brickell Biotech which values Vical at $40m but the market did not respond favorably to the announcement a...

Vical slips ( VICL -13.1% ) as the company announces  to merge with Brickell Biotech and create a pharmaceutical company focused on developing therapies primarily for dermatological disorders. More news on: Vical Incorporated, Healthcare stocks news, Merger & acquisition n...

DelMar Pharmaceuticals (NASDAQ: DMPI )  -41%  on equity offering . More news on: DelMar Pharmaceuticals, Inc., Vascular Biogenics Ltd., Centene Corporation, Stocks on the move, Read more ...